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Abstract
BACKGROUND: Testosterone deficiency in men is characterized by typical symptoms of hypogonadism and negative influ-
ence on the preservation of bone mass. In this study, we analysed the relationship between testosterone concentration and 
bone metabolism. Moreover, we assessed the impact of one-year compensation of testosterone deficiency in elderly men on 
bone metabolism and bone mineral density. Radioisotopic methods of bone metabolism assessment provide new research 
opportunities.
MATERIALS AND METHODS: Men with total testosterone concentration (TT) ≤ 3 ng/ml were included into this study. Patients 
with disorders or injuries of bone system, elevated prostate-specific antigen (PSA), enlarged prostate, disorders of thyroid and 
liver, diabetes mellitus or a history of chemotherapy as well as those treated for a long time with antibiotics were excluded 
from this study. The results of 50 men aged 57.52 ± 6.71 years obtained before the treatment (I test) and after one year of oral 
testosterone supplementation (test II) were analysed in this study. The following examinations and analyses were performed: 
interview and physical examination, orthopaedic, neurological and urological consultations, blood biochemistry, determination 
of hormones levels, assessment of Testosterone Deficiency Syndrome (TDS), densitometric and radioisotope assessment of 
bone metabolism. Moreover, radioisotopic index of bone metabolism was calculated.
Testosterone therapy with oral preparation Undestor Testo Caps (Organon) containing 40 mg of testosterone lasted for 12 
months. Statistical analysis was performed using Statistica 12 and Excel 2010 programs. Correlations between results before 
and after treatment were analysed.
RESULTS: After 12 months of treatment, testosterone concentration increased by mean 78% and the level of luteinizing hormone 
(LH) decreased by 62%. TDS index increased from 0.53 ± 0.21 (in test I) to 1.91 ± 0.60 (in test II). After the therapy this index 
was significantly higher in all men (p < 0.0001). Moreover, BMD was also improved following therapy, however, the difference 
between test I and II was statistically insignificant. The greatest change was found in case of IBM (Index of Bone Metabolism). 
We observed a positive correlation between IBM and BMD before treatment (r = 0.7991), however, its strength decreased after 
one-year therapy (r = 0.6757).
CONCLUSIONS: In our opinion, IBM is more sensitive than other methods of the assessment of changes occurring in bone 
system under the influence of testosterone therapy. The observed changes in IBM were proportional to changes in testosterone 
concentration. Testosterone level, TDS and radioisotopic assessment of bone metabolism may be used as prognostic and 
therapeutic factors of osteoporosis and bone fractures in elderly men.
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Introduction
Testosterone deficiency is characterized by typical symptoms of 
hypogonadism, it may be associated with the deterioration of quality 
of life and may negatively affect the function of many organs and 
systems. Over the age of 40, total testosterone (TT) concentration 
is reduced by mean 1% per year [1, 2].
In men, the correct concentration of sex hormones exerts ben-
eficial effects on the preservation of bone mass [3]. These find-
ings are well-known and have been presented in the literature 
[4–7]. However, there is still a need for further studies concerning 
the relationship between testosterone levels and bone metabolism 
which is the main factor in the process of bone remodelling. Un-
ravelling these associations can help to determine procedures of 
osteoporosis treatment in men. It is interesting how changes in the 
concentration of testosterone correlate with alterations in bone me-
tabolism and with the progression of osteoporosis. Radioisotopic 
methods of bone metabolism assessment provide new research 
possibilities. Along with the densitometry, they may contribute to the 
widening of the spectrum of analysis of bone turnover occurring in 
older men with testosterone deficiency. Therefore, we decided to 
take up this issue using wide spectrum of diagnostic tools.
Main objectives: the assessment of the impact of testosterone 
deficiency compensation in elderly men on metabolism and bone 
mineral density; the determination of correlation between bone 
mineral density (BMD) and radioisotopic index of bone metabolism 
(IBM) and the concentration of testosterone (T) in elderly men with 
low testosterone levels  treated with oral preparation of testosterone 
for a year; the inclusion of radioisotopic evaluation of bone metabo-
lism using own methods and programs into imaging diagnostics of 
osteoporosis in men with osteoporosis.
Materials and methods
In this study, the results of biochemical and hormonal tests of 
patients subjected to isotopic examination of bone system or 
densitometry were analysed. Also the records of patients with 
signs of hypogonadism referred to endocrinologist were evalu-
ated. A total of 317 patients’ records were examined. Men aged 
50–65 years with total testosterone concentration ≤ 3 ng/ml (nor-
mal range: 3 ≤ TT ≤ 10.6 ng/ml) were selected from this group. In 
order to confirm the reproducibility of results, TT level was tested 
two times (the second analysis was performed after 2 weeks from 
the first measurement). Blood samples were drawn in the morn-
ing (7–8 a.m.) after a nigh fasting. Patients with increased level of 
prostate-specific antigen (PSA) were excluded from further analysis. 
Study group contained only patients with PSA ≤ 3 ng/ml. All eligible 
participants underwent ultrasound examination of prostate and 
those with enlarged organ were also excluded from study. Also 
patients with skeletal disorders that may affect the metabolism, 
bone inflammation, arthritis, trauma, fractures and surgery within 
bone system, disorders of thyroid and liver, diabetes, history of 
chemotherapy or chronic intake of glucocorticosteroids and 
antibiotics were not enrolled into study. Control ultrasound ex-
amination of the prostate was performed additionally after 6 and 
12 months of therapy onset. Finally, the results of 50 male sub-
jects aged 57.52 ± 6.71 years obtained before treatment (test I) 
and after one year of oral testosterone supplementation (test II) were 
analysed. All eligible patients were informed about the purpose and 
methods of the study. Each of them provided written consent to 
participate in the study and to publish its anonymous results. The 
study was approved by Bioethics Committee of Medical University 
(protocol no. RNN/123/09/KB).
Basic research and consultations:
 — interview and physical examination (age, height, weight, BMI)
 — orthopaedic, neurological and urological consultations
Parameters determined in the serum
 — biochemical analysis included: ionized calcium (Ca2+), vitamin 
D3, phosphates (P), gamma-glutamyl transpeptidase (GGTP), 
aspartate aminotransferase (AspAT) (glutamic oxoloacetic 
transaminase), alanine aminotransferase (ALAT) (glutamic 
pyruvic transferase), amylase, glucose and cholesterol (chol). 
The determination of the concentration of aforementioned pa-
rameters was performed with the use of reagents from Bor-Pol 
Gliwice, and the measurement was made on A15 analyzer 
(BioSystems).
 — analysis of hormones included: total testosterone (TT), pros-
tate-specific antigen (PSA), luteinizing hormone (LH), thyroid 
stimulating hormone (TSH), dehydroepiandrosterone sulphate 
(DHEA-S). The determination of hormones levels was performed 
using ELFA (Enzyme Linked Fluorescent Assay) technique and 
bioMérieux reagents.
Testosterone Deficiency Syndrome (TDS) was calculated 
using the following formula:
testosterone concentration (ng/ml)/LH concentration (mlU/ml). 
TDS value < 1 is considered as hormonal indicator of age-related 
hypogonadism [2].
Densitometric examination
Densitometry was performed with DEXA (Dual Energy X-ray 
Absorptiometry) technique on NORLAND X46 densitometer. Bone 
mineral density (BMD) and the T-score of femoral bone neck were 
measured.
Radioisotopic analysis of bone metabolism
Radioisotope analysis of bone system was performed with 
Philips Brightview XCT gamma camera (Philips, Guildford, UK) 
using own method and a developed program — BONS. The study 
involved dynamic acquisition of femoral bone performed in rear 
projection after the injection of radiopharmaceutical (Tc99mMDP) with 
an activity of 11 MBq/kg of body mass as well as static acquisi-
tions performed after 180 min. from radiopharmaceutical injection.
Following the analysis of data obtained using the developed 
BONS program and static and dynamic bone scintigrams, radio-




IBM — radioisotopic index of bone metabolism;  Gtot — number 
of counts per one matrix pixel in the study of the whole body;  Groi 
— number of counts per one matrix pixel in the selected area of 
interest (ROI); T0 — time of dynamic phase beginning; T1 — time 
of static phase beginning.
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IBM is dimensionless and its normal range  for healthy men 
is 87.31 ≤ IBM ≤ 104.79. The method of the determination of radio-
isotopic index of bone metabolism (IBM) and results obtained in 
studies of healthy subjects and patients with various diseases have 
been published in the literature [8–11].
Testosterone therapy
Study participants received oral preparation Undestor 
Testo Caps (Organon) containing 40 mg of testosterone for 
12 months during morning and evening meals.
Statistical analysis
Statistical analysis of data was performed using Excel 2010 
and Statistica 12 (pl). Mean value, median and standard deviation 
were calculated. The Shapiro-Wilk test was used to verify normal 
distribution of variables. ANOVA test was used for the compari-
son of data showing no departures from normality. Mean value, 
median, maximum and minimum values and standard deviation 
were calculated for measurable variables. Correlations between 
results obtained before and after treatment were analysed. All 
calculations were performed using 95% confidence area.
Results
The results of preliminary study are presented in Table 1.
The distribution of BMI values in tests I and II was normal. In 
test I, 10 patients had normal body mass, 26 were overweight and 
14 were obese. In test II (post-treatment), 14 men had normal body 
mass, 28 were overweight and 8 were obese. Slightly reduced BMI 
was observed in 19 patients in test II in comparison to test I. How-
ever, this difference in BMI was not statistically significant (p < 0.05).
The results of densitometry are presented in Table 2.
The distribution of BMD values in tests I and II was normal. In 
test I, normal bone mineral density was found in 11 patients, in 24 
patients osteopenia was observed, while osteoporosis was found 
in 15 men. In test II, normal bone mineral density was found in 14 
patients, osteopenia — in 25 patients, while osteoporosis — in 
11 men. There were no statistically significant differences in BMD 
between test I and II (p < 0.05).
In this study, a positive correlation between IBM and BMD 
was observed (r = 0.7991). After one year of testosterone supple-
mentation the strength of this correlation decreased (r = 0.6757), 
which can be due to a lower accuracy of densitometric assessment 
of BMD in comparison to radioisotopic assessment of IBM.
The results of biochemical and hormonal parameters analy-
ses are presented in Table 3.
All results of biochemical and hormonal parameters analy-
ses performed before and after the treatment were within normal 
range. Differences between the results of test I and II were sta-
tistically insignificant, except for P in case of which the difference 
was significant (p = 0.0087). IBM values and their scattering in 
test I vs. test II are shown in Figure 1. In both tests, the distribu-
tion of IBM values was normal. In test I, IBM below the lower limit 
of the normal range was found in 18 patients (36%). In test II, the 
increase in radioisotopic index of bone metabolism value was ob-
served in all patients. However, the results of 7 men (14%) were 
still below the normal range. The rest of the results were within 
the normal range. The difference in IBM before treatment (test I) 
and after therapy (test II) was statistically significant (p < 0.0001). 
No results exceeding the upper level of norm were observed. 
A strong correlation between IBM in tests I and II as well as the 
ascending regression line (Fig. 1) indicate the increase in bone 
metabolism index in all subjects. LH and TT values and their 
Table 1. The results of anthropometric examination
N = 50 Age [years] Weight [kg] Height [cm] BMI
Test I 57.52 ± 6.71 85.40 ± 9.69 175.18 ± 6.32 27.85 ± 3.01
Test II 57.52 ± 6.71 84.20 ± 8.80 175.18 ± 6.32 27.45 ± 2.65
p ns ns ns ns
Table 2. The results of densitometric examination
N = 50 BMD [g/cm2]
Test I 0.8913 ± 0.0748
Test II 0.8995 ± 0.0799
Table 3. The results of biochemical and hormonal parameters analyses
n = 50 Normal range Test I Test II p
PSA 0 ÷ 4 [ng/ml] 1.75 ± 0.83 1.83 ± 0.89 ns
TSH 0.3 ÷ 4 [mU/ml] 2.31 ± 1.17 2.61 ± 1.65 ns
DHEA-S 880 ÷ 3180 [ng/ml] 1756 ± 426 1956 ± 826 ns
Ca2+ 0.98 ÷ 1.13 [mmol/l] 1.03 ± 0.03 1.01 ± 0.04 ns
P 2.5 ÷ 4.8 [mg/dl] 3.25 ± 0.47 3.01 ± 0.52 0.0087
GGTP 11 ÷ 50 [U/l] 29.89 ± 9.07 32.11 ± 6.42 ns
AspAT 12 ÷ 40 [U/l] 29.11 ± 5.22 30.56 ± 5.81 ns
cholesterol 150 ÷ 250 [ng/dl] 209 ± 33.18 201 ± 36.22 ns
glucose 55 ÷ 100 [mg/dl] 82.44 ± 9.65 80.18 ± 6.19 ns
ALAT 9 ÷ 40 [U/l] 31.01 ± 5.82 28.83 ± 7.51 ns
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scatter are presented in Figure 2. In test I, mean testosterone 
level in the study group was 2.27 ± 0.56 ng/ml, while LH value 
was 4.64 ± 1.03 mlU/ml. A negative correlation with medium 
strength was observed between LH and TT values. TT and LH 
values after one year testosterone therapy (test II) are presented 
in Figure 3. In test II, mean testosterone value in study group 
was 4.06 ± 0.78 ng/ml, while LH value was 2.22 ± 0.37 mlU/ml. 
After 12 months of testosterone supplementation (test II), the 
increase in testosterone was observed in comparison to test 
I (before treatment). Mean increase in TT value after the therapy 
was 78%, and the difference in levels between test I and test II 
was statistically significant (p = 0.0001). At the same time, the 
decrease in LH by mean 62% was seen, and the difference be-
tween test I and test II was statistically significant (p = 0.0001). 
Similarly to test I, the correlation between LH and TT values in 
test II was negative, however, it was of lower strength. The de-
crease in the strength of the correlation may indicate different 
individual-related influence of one-year testosterone treatment on 
the increase of testosterone concentration and the decrease in LH 
levels. Changes in the calculated index of testosterone deficiency 
— TDS — before and after the therapy are presented in Figure 4. 
Before treatment, TDS < 1 was observed in all study participants. 
Mean value of TDS was 0.53 ± 0.21. After therapy, this index 
was higher than 1 in all men, and its mean value was 1.91 ± 0.60. 
Vitamin D3 values and their scatter in relation to IBM values in test 
I are presented in Figure 5. Before treatment, we observed a strong 
positive correlation between D3 and IBM values. We also found 
a positive correlation between D3 and BMD values (r = 0.6451). 
In patients with osteoporosis, levels of vitamin D3 were below 
the lower limit of norm. The increase in vitamin D3 concentration 
was accompanied by the increase in bone mineral density. Vitamin 
D3 values and their scatter in relation to IBM in test II are presented 
in Figure 6. After treatment, we observed a strong positive correla-
tion between D3 and IBM values. Its strength slightly decreased in 
comparison with test I (r = 0.8452). Correlation between D3 and 
BMD values was positive and it had similar strength to the cor-
relation before therapy (r = 0.6528). In patients with osteoporosis, 
vitamin D3 values were below the lower limit of norm. Again, the 
increase in vitamin D3 concentration was accompanied by the 
increase in bone mineral density.
Figure 3. The scatter of LH vs. TT values in test II
Figure 4. Testosterone deficiency syndrome in test I and II
Figure 1. The scattering of IBM values in test II vs. test I
Figure 2. The scatter of LH vs. TT values in test I 




In men, androgens exert a great impact on bone system 
throughout the life. The highest concentration of testosterone 
is reached between 25 and 30 years and then the slow reduction 
by 0.4–0.8% per year in total testosterone and by about 1.3–2% 
in free testosterone is observed. Late hypogonadism occurs over 
the age of 60 yrs. The reduction in testosterone levels with age 
exacerbates muscle weakness and muscle mass loss and leads to 
osteopenia and osteoporosis [12–17]. There are a number of 
methods assessing changes in bone system [18, 19]. Densito-
metry is the most common and generally available one. However, 
its sensitivity is low. In this study, T-score index was used only in 
the differentiation between normal bone density, osteopenia and 
osteoporosis. In turn, the method of radioisotopic assessment of 
bone metabolism (developed by authors) is a sensitive indicator 
of changes in bone metabolic processes. The results of our study 
show that densitometry is less sensitive than radioisotopic assess-
ment of bone metabolism.
TDS index, which is included in endocrinology guidelines and 
provides additional diagnostic value, was used during the design of 
testosterone therapy. When TDS is below 1, testosterone replace-
ment therapy should last 6–12 months. In this study, testosterone 
supplementation lasted for 12 months. Before final qualification to 
study group, a number of tests were performed in order to exclude 
men with disorders that may result in the lowering of testosterone 
levels. Study group comprised 50 men with reduced testosterone 
levels and no other comorbidities. Clinical features of testosterone 
deficiency and hypogonadism were confirmed using TDS index 
(Fig. 4), which value did not exceed 1. After 12 months of oral 
testosterone therapy, a significant increase in its value was ob-
served. Before treatment, TDS was 0.53 ± 0.21, and after therapy 
it was 1.91 ± 0.60. This change was associated with the rise in tes-
tosterone concentration by mean 78% and simultaneous decrease 
in LH level by mean 62%. The greatest increase in TT following 
therapy was observed in men with lowest baseline concentration 
of testosterone. Change in bone mineral density in densitometry 
was small and changes between test I and II were not statistically 
significant. The analysis of radioisotope index of bone metabolism 
was included in the assessment of bone turnover. In this analysis, the 
greatest change was found in case of IBM values (Fig. 1). After the 
therapy, we observed a statistically significant increase in its level in 
all participants in comparison with test I (p < 0.0001). In our opinion, 
IBM is more sensitive than other methods assessing changes oc-
curring in bone system after one year of testosterone treatment.
In studies in which other treatment methods were used, mean 
increase in TT concentration was in the range of 88 ÷ 128% [2].
Conclusions
1. In men with hypogonadism, one year of oral testosterone 
therapy in the dose 40 mg/day significantly increased its total 
plasma level. Changes observed in IBM were proportional to 
the increase in TT concentration.
2. Radioisotopic method of bone metabolism (IBM) assessment 
is a sensitive and useful method in the diagnosis of bone 
turnover in patients treated with testosterone.
3. TT, TDS and IBM values may be prognostic and therapeutic 
factors of osteoporosis and bone fractures in elderly men.
Source of founding
The study was performed within the investigations and statu-
tory activity of the Department of Diagnostics and Radiological and 
Isotopic Therapy, Medical University, Lodz.
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